Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity

Fersino, S.; Tebano, Umberto; Mazzola, Rosario; Giaj-Levra, Niccolò; Ricchetti, F.; Paola, Gioacchino Di; Fiorentino, Alba; Sicignano, G.; Naccarato, S.; Ruggieri, R.; Cavalleri, Stefano; Alongi, Filippo

doi:10.1016/j.clgc.2017.01.025

Cited by 40 publications

(29 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seventeen eligible studies were included. (19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35) These retrospective (20, 23-25, 27, 30, 34) [7] and prospective (19,21,22,26,28,29,(31)(32)(33)35) [10] trials had heterogeneous characteristics in terms of dose, target definition and combination with hormonal therapy. Median follow-up ranged between 11.5 and 111.0 months (median: 30.0 months).…”

Section: Resultsmentioning

confidence: 99%

Postoperative Hypofractionated Radiation Therapy in Prostate Carcinoma: A Systematic Review

Siepe

Buwenge

Nguyen

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Postoperative Hypofractionated Radiation Therapy in Prostate Carcinoma: A Systematic Review

Siepe

Buwenge

Nguyen

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Clinical experiences in PC RT by means of intensitymodulated and image-guided techniques (IMRT-IGRT) have demonstrated a lower probability of RT-related adverse events [4][5][6]. These RT-technological and technical advances have allowed clinicians to deliver higher radiation doses to the target with similarly limited toxicities.…”

Section: Introductionmentioning

confidence: 99%

1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Unity Elekta is a unique magnetic resonance (MR)-linac that conjugates a 1.5 Tesla MR unit with a 7 MV flattening filter free accelerator.A prospective observational study for the clinical use of Elekta Unity is currently ongoing in our department. Herein, we present our preliminary report on the feasibility, quality of life, and patientreported outcomes measures (PROMs) for localized prostate cancer (PC) treated with stereotactic body radiotherapy (SBRT). Methods: The SBRT protocol consisted of a 35 Gy schedule delivered in 5 fractions within 2 weeks. Toxicity and quality of life (QoL) were assessed at baseline and after treatment using the Common Terminology Criteria for Adverse Events v5.0, International Prostatic Symptoms Score (IPSS), ICIQ-SF, IIEF-5, and EORTC-QLQ-C30 and PR-25 questionnaires. Results: Between October 2019 and January 2020, 25 patients with localized PC were recruited. The median age was 68 years (range, 54-82); 4 were low risk, 11 favorable intermediate risk (IR) and 10 unfavorable IR. Median iPSA was 6.8 ng/ml (range, 1-19), and 9 of these patients (36%) received concurrent androgen deprivation therapy. Median prostate volume was 36 cc (range, 20-61); median baseline IPSS was 5 (range, 0-10). Median time for fraction was 53 min (range, 34-86); adaptive strategy with daily critical structure and target re-contouring and daily replanning (adapt to shape) was performed in all cases. No grade ≥ 3 adverse event was observed, three patients (12%) reported grade 2 acute genitourinary toxicity (urinary frequency, urinary tract pain and urinary retention), while only one patient reported mild rectal pain. No relevant deteriorations were reported in PROMs.

show abstract

“…Clinical experiences in PC RT by means of intensity-modulated and image-guided techniques (IMRT-IGRT) have demonstrated a lower probability of RT-related adverse events [4][5][6]. These RTtechnological and technical advances have allowed clinicians to deliver higher radiation doses to the target with similarly limited toxicities.…”

Section: Introductionmentioning

confidence: 99%

1.5T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment

Alongi

Rigo

Figlia

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background Unity Elekta is a unique magnetic resonance (MR)-linac that conjugates a 1.5 Tesla MR unit with a 7 MV flattening filter free accelerator.A prospective observational study for the clinical use of Elekta Unity is currently ongoing in our department. Herein, we present our preliminary report on the feasibility, quality of life, and patient-reported outcomes measures (PROMs) for localized prostate cancer (PC) treated with stereotactic body radiotherapy (SBRT). Methods The SBRT protocol consisted of a 35 Gy schedule delivered in 5 fractions within two weeks. Toxicity and quality of life (QoL) were assessed at baseline and after treatment using the Common Terminology Criteria for Adverse Events v5.0, International Prostatic Symptoms Score (IPSS), ICIQ-SF, IIEF-5, and EORTC-QLQ-C30 and PR-25 questionnaires. Results Between October 2019 and January 2020, 25 patients with localized PC were recruited. The median age was 68 years (range, 54-82); 4 were low risk, 11 favorable intermediate risk (IR) and 10 unfavorable IR. Median iPSA was 6.8 ng/ml (range, 1-19), and 9 of these patients (36%) received concurrent androgen deprivation therapy. Median prostate volume was 36 cc (range, 20-61); median baseline IPSS was 5 (range, 0-10). Median time for fraction was 53 minutes (range, 34-86); adaptive strategy with daily critical structure and target re-contouring and daily replanning (adapt to shape) was performed in all cases. No grade ≥ 3 adverse event was observed, three patients (12%) reported grade 2 acute genitourinary toxicity (urinary frequency, urinary tract pain and urinary retention), while only one patient reported mild rectal pain. No relevant deteriorations were reported in PROMs. Conclusion To the best of our knowledge, this is the first experience reporting feasibility, clinician-reported outcome measurements, and PROMs for 1.5T MR-guided adaptive SBRT for localized prostate cancer. The preliminary data collected here report optimal safety and excellent tolerability, as also confirmed by PROMs questionnaires. Moreover, the data on technical feasibility and timing of online daily adapted planning and delivery are promising. More mature data are warranted.

show abstract

Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity

Cited by 40 publications

References 27 publications

Postoperative Hypofractionated Radiation Therapy in Prostate Carcinoma: A Systematic Review

Postoperative Hypofractionated Radiation Therapy in Prostate Carcinoma: A Systematic Review

1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment

1.5T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment

Contact Info

Product

Resources

About